Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

The study is the largest to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy. It analyzes real-world data from the American Academy of Ophthalmology IRIS® Registry and demonstrates sustained intraocular pressure reductions and decreased medication dependence

MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI® Surgical System (“OMNI”) in managing primary open-angle glaucoma (“POAG”). This study, in press in the American Journal of Ophthalmology and based on data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), presents compelling evidence supporting the sustained benefits of standalone canaloplasty and trabeculotomy with OMNI, independent of cataract surgery.

This real-world study, led by Nathan M. Radcliffe, MD, of Mount Sinai School of Medicine in New York City, evaluated 230 eyes of 196 patients with POAG through up to 36 months. The results demonstrate clinically and statistically significant reductions in intraocular pressure (“IOP”) through up to 36 months postoperatively, with mean reductions ranging from 5.6 to 7.1 mmHg. The study also reports a statistically significant decrease in medication use through 18 months. Eyes with lower baseline IOP experienced medication reduction through 36 months.

“There is a growing interest in using minimally invasive glaucoma surgery (“MIGS”) as a standalone procedure for patients with pseudophakic or precataractous eyes,” said Nathan M. Radcliffe, MD, lead investigator of the study and Associate Professor at the Mt. Sinai School of Medicine in New York. “This analysis represents one of the most comprehensive, real-world evaluations of standalone canaloplasty and trabeculotomy in these patient populations to date. Our findings underscore the ability of OMNI to achieve significant and sustained reductions in IOP and medication use over three years, reinforcing its position as a highly effective interventional treatment for patients with primary open-angle glaucoma.”

Key Study Findings:

• Sustained IOP Reduction: Mean (SD) baseline IOP was 22.1 (6.4) mmHg. Over 36 months of follow-up, mean IOP ranged from 15.1 to 16.7 mmHg (p